Table 1.

Hazard ratios for breast cancer–specific mortality, stratified by race

White (n = 631)African American (n = 518)
HR adjusted for age at diagnosis and date of diagnosis (95% CI)HR adjusted for age at diagnosis, date of diagnosis, and stage at diagnosis (95% CI)HR adjusted for age at diagnosis and date of diagnosis (95% CI)HR adjusted for age at diagnosis, date of diagnosis, and stage at diagnosis (95% CI)
Menopausal status
 Premenopausal1.001.001.001.00
 Postmenopausal0.6 (0.3–1.0)0.6 (0.3–1.0)0.8 (0.5–1.3)0.8 (0.5–1.3)
Subtype
 Luminal A1.001.001.001.00
 Luminal B1.6 (0.9–2.9)1.5 (0.8–2.7)1.3 (0.6–2.4)1.2 (0.6–2.2)
 Basal-like2.0 (1.2–3.4)1.7 (1.0–2.9)1.5 (1.0–2.4)1.4 (0.9–2.1)
 HER2+/ER2.4 (1.2–4.7)1.4 (0.7–2.9)2.3 (1.3–4.0)1.8 (1.0–3.1)
 Unclassified1.6 (0.9–3.1)1.6 (0.9–3.1)1.3 (0.8–2.3)1.2 (0.7–2.0)
Subtype combined
 Luminal A or B1.001.001.001.00
 Basal-like1.8 (1.1–3.0)1.6 (0.9–2.6)1.5 (1.0–2.2)1.3 (0.9–2.0)
 HER2+/ER2.1 (1.1–4.2)1.3 (0.6–2.6)2.2 (1.3–3.7)1.7 (1.0–2.9)
ER status
 ER+1.001.001.001.00
 ER1.5 (1.0–2.2)1.3 (0.9–1.9)1.7 (1.2–2.5)1.5 (1.0–2.2)
PR status
 PR+1.001.001.001.00
 PR1.8 (1.2–2.7)1.6 (1.1–2.4)1.6 (1.1–2.3)1.4 (0.9–2.0)
HER2 status
 HER21.001.001.001.00
 HER2+1.5 (0.9–2.3)1.2 (0.7–1.9)1.4 (0.9–2.2)1.3 (0.8–1.9)